JP2023527209A - がんの治療 - Google Patents

がんの治療 Download PDF

Info

Publication number
JP2023527209A
JP2023527209A JP2022573285A JP2022573285A JP2023527209A JP 2023527209 A JP2023527209 A JP 2023527209A JP 2022573285 A JP2022573285 A JP 2022573285A JP 2022573285 A JP2022573285 A JP 2022573285A JP 2023527209 A JP2023527209 A JP 2023527209A
Authority
JP
Japan
Prior art keywords
lag
protein
derivative
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527209A5 (https=
Inventor
トリーベル，フレデリック
Original Assignee
イムテップ エス．アー．エス．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008037.0A external-priority patent/GB202008037D0/en
Priority claimed from GBGB2018062.6A external-priority patent/GB202018062D0/en
Application filed by イムテップ エス．アー．エス． filed Critical イムテップ エス．アー．エス．
Publication of JP2023527209A publication Critical patent/JP2023527209A/ja
Publication of JP2023527209A5 publication Critical patent/JP2023527209A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022573285A 2020-05-28 2021-03-24 がんの治療 Pending JP2023527209A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2008037.0A GB202008037D0 (en) 2020-05-28 2020-05-28 Treatment of cancer
GB2008037.0 2020-05-28
RU2020131384 2020-09-23
RU2020131384A RU2020131384A (ru) 2020-05-28 2020-09-23 Лечение рака
GB2018062.6 2020-11-17
GBGB2018062.6A GB202018062D0 (en) 2020-11-17 2020-11-17 Treatment of cancer
PCT/EP2021/057588 WO2021239292A1 (en) 2020-05-28 2021-03-24 Treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023527209A true JP2023527209A (ja) 2023-06-27
JP2023527209A5 JP2023527209A5 (https=) 2024-04-05

Family

ID=75362569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573285A Pending JP2023527209A (ja) 2020-05-28 2021-03-24 がんの治療

Country Status (11)

Country Link
US (1) US20230210946A1 (https=)
EP (1) EP4157313A1 (https=)
JP (1) JP2023527209A (https=)
KR (1) KR20230028321A (https=)
CN (1) CN116133674A (https=)
AU (1) AU2021280214A1 (https=)
BR (1) BR112022024179A2 (https=)
CA (1) CA3184309A1 (https=)
IL (1) IL298507A (https=)
MX (1) MX2022014909A (https=)
WO (1) WO2021239292A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475955A1 (en) * 2022-02-11 2024-12-18 Immutep S.A.S. Treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540616A (ja) * 2007-10-05 2010-12-24 イムテップ 単球免疫応答を誘発するための、組換えｌａｇ−３タンパク質またはその誘導体の使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP2021534177A (ja) * 2018-08-16 2021-12-09 ジー１ セラピューティクス， インコーポレイテッド 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540616A (ja) * 2007-10-05 2010-12-24 イムテップ 単球免疫応答を誘発するための、組換えｌａｇ−３タンパク質またはその誘導体の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUTURE ONCOL., vol. vol.15, issue 17, JPN6025011423, 2019, pages 1963 - 1973, ISSN: 0005555943 *
J. TRANSL. MED., vol. 8, JPN6025011422, 2010, pages 1 - 11, ISSN: 0005752156 *

Also Published As

Publication number Publication date
KR20230028321A (ko) 2023-02-28
US20230210946A1 (en) 2023-07-06
IL298507A (en) 2023-01-01
AU2021280214A1 (en) 2023-02-02
EP4157313A1 (en) 2023-04-05
CA3184309A1 (en) 2021-12-02
CN116133674A (zh) 2023-05-16
MX2022014909A (es) 2023-03-06
BR112022024179A2 (pt) 2023-02-07
WO2021239292A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20210161844A1 (en) Compositions containing tucaresol or its analogs
AU2009210656A1 (en) Use of picoplatin and cetuximab to treat colorectal cancer
WO2024163641A2 (en) Formulations for treating cancer
JP2016515619A (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
WO2024163751A1 (en) Formulations for treating cancer
US12097199B2 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
WO2012106379A1 (en) Sensitization of cancer cells to treatment
JP2023527209A (ja) がんの治療
JP2025507017A (ja) 胃がんにおける抗ヒトｃｄ３９抗体、抗ヒトｐｄ－１抗体、及び化学療法による併用
US20240277804A1 (en) Triple combination therapy
US20250368714A1 (en) Treatment of cancer
US11696936B2 (en) Treatment of cancer
CN118804760A (zh) 癌症的治疗
Karampeazis et al. A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20221228

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413